Clinical application of carbon nanoparticles suspension in papillary thyroid carcinoma

doi:10.3877/cma.j.issn.1674-0793.2014.06.008

Abstract

Abstract:

Objective

To study the detected number of overall and metastatic lymph nodes and the negatively-stained parathyroid glands with the carbon nanoparticles injection.

Methods

This retrospective analysis included the clinical and pathological data of 284 patients. Among them, 70 were injected with carbon nanoparticles suspension (the trial group), the other 214 patients undergoing conventional surgery (the control group). Routine pathological examination was adopted in all resected specimens.

Results

The total number of detected lymph nodes was 1 841 and 2 828 in the two groups, respectively. The lymph nodes detection rate of the trial group was superior to that of the control group (Z=-4.112, P<0.01) .There were 481 and 754 metastatic lymph nodes detected in the trial group and control group; the detection rate of the trial group was superior to that of the control group (Z=-2.457, P=0.014). The lymph nodes and metastatic lymph nodes of level VI detection rate of the trial group were superior to those of the control group (Z=-3.819, P<0.01). Pathologic results of the specimens showed that parathyroid glands tissues were less found in the trial group than the control group, 25.7% and 39.7% respectively(Z=-2.521, P=0.012) .

Conclusion

Carbon nanoparticles suspension can increase the detection of overall lymph nodes in thyroid operations and it is an economic, less traumatic approach to protect the parathyroid glands.

Key words: Papillary thyroid carcinoma, Carbon nanoparticles, Lymphatic metastasis, Parathyroid glands

Weiye Deng, Hao Li, Yanfeng Chen, Wanli Liu, Anhua Li, Qiuli Li, Haiyan Huang, Jianwei Wang, Shaojian Lin, Yunfei Gao, Zhuming Guo. Clinical application of carbon nanoparticles suspension in papillary thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2014, 08(06): 451-455.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2014.06.008

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2014/V08/I06/451

Figures/Tables 2

References 19

[1]	Tuttle RM,Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm[J]. Endocrinol Metab Clin North Am, 2008, 37(2): 419-435, ix-x.
[2]	Mazzaferri EL,Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab, 2001, 86(4): 1447-1463.
[3]	Di Fabio F,Casella C,Bugari G, et al. Identification of patients at low risk for thyroidectomy-related hypocalcemia by intraoperative quick PTH[J]. World J Surg, 2006, 30(8): 1428-1433.
[4]	Sorgato N,Pennelli G,Boschin IM, et al. Can we avoid inadvertent parathyroidectomy during thyroid surgery?[J]. In Vivo, 2009, 23(3): 433-439.
[5]	Hao RT,Chen J,Zhao LH, et al. Sentinel lymph node biopsy using carbon nanoparticles for Chinese patients with papillary thyroid microcarcinoma[J]. Eur J Surg Oncol, 2012, 38(8): 718-724.
[6]	Liu CL,Yang TL,Chen BF. Sentinel lymph node mapping with emulsion of activated carbon particles in patients with pre-mastectomy diagnosis of intraductal carcinoma of the breast[J]. J Chin Med Assoc, 2003, 66(7): 406-410.
[7]	Giuliano AE,Hunt KK,Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6): 569-575.
[8]	Veronesi U,Viale G,Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study[J]. Ann Surg, 2010, 251(4): 595-600.
[9]	Catarci M,Guadagni S,Zaraca F, et al. Prospective randomized evaluation of preoperative endoscopic vital staining using CH-40 for lymph node dissection in gastric cancer[J]. Ann Surg Oncol, 1998, 5(7): 580-584.
[10]	Cai HK,He HF,Tian W, et al. Colorectal cancer lymph node staining by activated carbon nanoparticles suspension in vivo or methylene blue in vitro[J]. World J Gastroenterol, 2012, 18(42):6148-6154.
[11]	He J,Li S,Shao W, et al. Activated carbon nanoparticles or methylene blue as tracer during video-assisted thoracic surgery for lung cancer can help pathologist find the detected lymph nodes[J]. J Surg Oncol, 2010, 102(6): 676-682.
[12]	Yang Q,Wang XD,Chen J, et al. A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer[J]. Tumour Biol, 2012, 33(6): 2341-2348.
[13]	Hagiwara A,Takahashi T,Sawai K, et al. Lymph nodal vital staining with newer carbon particle suspensions compared with India ink: experimental and clinical observations[J]. Lymphology, 1992, 25(2): 84-89.
[14]	Asin L,Ibarra MR,Tres A, et al. Controlled cell death by magnetic hyperthermia: effects of exposure time, field amplitude, and nanoparticle concentration[J]. Pharm Res, 2012, 29(5): 1319-1327.
[15]	Madru R,Kjellman P,Olsson F, et al. 99mT_c-labeled superpara-magnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes[J]. J Nucl Med, 2012, 53(3): 459-463.
[16]	Hay ID,Thompson GB,Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2 444 consecutively treated patients[J]. World J Surg, 2002, 26(8): 879-885.
[17]	Vassiliou I,Tympa A,Arkadopoulos N, et al. Total thyroidectomy as the single surgical option for benign and malignant thyroid disease: a surgical challenge[J]. Arch Med Sci, 2013, 9(1): 74-78.
[18]	Chao TC,Jeng LB,Lin JD, et al. Reoperative thyroid surgery[J]. World J Surg, 1997, 21(6): 644-647.
[19]	Guerrero MA,Suh I,Vriens MR, et al. The number of needle passes affects the accuracy of parathyroid hormone assay with intraoperative parathyroid aspiration[J]. Am J Surg, 2010, 200(6): 701-705.

临床病理特征		试验组	对照组	χ²值	P值
性别		?	?	0.817	0.368
?	男	19	64	?	?
?	女	51	150	?	?
年龄（岁）		?	?	0.035	0.852
?	<45	40	125	?	?
?	≥45	30	89	?	?
TNM分期		?	?	4.166	0.969
?	Ⅰ	54	164	?	?
?	Ⅱ	3	6	?	?
?	Ⅲ	5	21	?	?
?	Ⅳ	8	23	?	?
肿瘤浸润		?	?	3.820	0.431
?	T1	56	159	?	?
?	T2	11	33	?	?
?	T3	1	17	?	?
?	T4	2	5	?	?
淋巴结转移		?	?	3.286	0.193
?	N0	24	79	?	?
?	N1	18	73	?	?
?	N2	28	62	?	?
远处转移		?	?	0.697	0.404
?	M0	69	213	?	?
?	M1	1	1	?	?
手术方式		?	?	6.463	0.069
?	L+CND	23	98	?	?
?	L+CND+CLND	18	43	?	?
?	T+CND	7	30	?	?
?	T+CND+CLND	22	43	?	?

临床病理特征		试验组	对照组	χ²值	P值
性别		?	?	0.817	0.368
?	男	19	64	?	?
?	女	51	150	?	?
年龄（岁）		?	?	0.035	0.852
?	<45	40	125	?	?
?	≥45	30	89	?	?
TNM分期		?	?	4.166	0.969
?	Ⅰ	54	164	?	?
?	Ⅱ	3	6	?	?
?	Ⅲ	5	21	?	?
?	Ⅳ	8	23	?	?
肿瘤浸润		?	?	3.820	0.431
?	T1	56	159	?	?
?	T2	11	33	?	?
?	T3	1	17	?	?
?	T4	2	5	?	?
淋巴结转移		?	?	3.286	0.193
?	N0	24	79	?	?
?	N1	18	73	?	?
?	N2	28	62	?	?
远处转移		?	?	0.697	0.404
?	M0	69	213	?	?
?	M1	1	1	?	?
手术方式		?	?	6.463	0.069
?	L+CND	23	98	?	?
?	L+CND+CLND	18	43	?	?
?	T+CND	7	30	?	?
?	T+CND+CLND	22	43	?	?

淋巴结检出数		试验组	对照组	Z值	P值
例数		70	214	?	?
总检出淋巴结数/转移淋巴结数		1841/481	2828/754	?	?
?	总淋巴结数	17（7，37）	7 （4，19）	-4.112	<0.001^b
?	转移淋巴结数	2（ 0，8 ）	1 （0，4）	-2.457	0.014^b
总检出侧颈淋巴结数/转移淋巴结数		1 192/220	1 624/375	?	?
?	总淋巴结数	28（10，43）	2（0，8）	-2.963	0.079
?	转移淋巴结数	18（10，28）	3（0，7）	-1.626	0.937
总检出Ⅵ区淋巴结数/转移淋巴结数		634/253	1 184/375	?	?
?	总淋巴结数	9（4，13）	2（0，5）	-3.819	<0.05^b
?	转移淋巴结数	5（3，8）	1（0，3）	-2.521	0.012^b

淋巴结检出数		试验组	对照组	Z值	P值
例数		70	214	?	?
总检出淋巴结数/转移淋巴结数		1841/481	2828/754	?	?
?	总淋巴结数	17（7，37）	7 （4，19）	-4.112	<0.001^b
?	转移淋巴结数	2（ 0，8 ）	1 （0，4）	-2.457	0.014^b
总检出侧颈淋巴结数/转移淋巴结数		1 192/220	1 624/375	?	?
?	总淋巴结数	28（10，43）	2（0，8）	-2.963	0.079
?	转移淋巴结数	18（10，28）	3（0，7）	-1.626	0.937
总检出Ⅵ区淋巴结数/转移淋巴结数		634/253	1 184/375	?	?
?	总淋巴结数	9（4，13）	2（0，5）	-3.819	<0.05^b
?	转移淋巴结数	5（3，8）	1（0，3）	-2.521	0.012^b

Please choose a citation manager

Content to export